We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Autism-Risk Screening Services Guide Physicians and Families

By LabMedica International staff writers
Posted on 10 Dec 2012
A new clinical partnership offers chromosomal microarray analysis as a first-line genetic test as part of a comprehensive diagnostic evaluation of individuals with autism spectrum disorders (ASDs).

The FirstStepDx genetic test offered to patients and their families is a whole-genome genetic test customized with validated, novel, proprietary, genetic variants associated with ASDs. More...
The genetic test now is available as a fast and painless cheek swab (FirstStep Buccal), eliminating the need for a blood draw.

The Center for Autism and Related Disorders (CARD; Los Angeles, CA, USA) and Lineagen (Salt Lake City, UT, USA) launched a clinical partnership for children on the autism spectrum. Under the terms of the partnership agreement, FirstStep, integrated with a pre-and post-test genetic counseling service and personalized reporting, will be offered to patients receiving treatment in CARD's innovative Skills program.

CARD is a provider of early intensive behavioral intervention for individuals with ASDs. Lineagen is a molecular diagnostics company focused on integrated genetic testing and counseling for individuals with ASDs and other disorders of childhood development.

Michael S. Paul, PhD, Lineagen's CEO, stated, "We are very pleased to initiate our clinical partnership program with CARD. Identification of genetic variants associated with ASDs, as well as other disorders of childhood development, with our FirstStep test furthers the understanding of the etiology for these disorders and may aid physicians and treatment specialists to more accurately guide clinical management. We look forward to providing children who are receiving the best treatment at CARD with the best genetic testing and genetic counseling service currently available."

CARD was founded by autism expert and clinical psychologist Doreen Granpeesheh, PhD, BCBA-D. CARD treats individuals with ASD using the principles and procedures of Applied Behavior Analysis (ABA), which has been empirically proven to be the most effective method for treating individuals with ASD and is recommended by the American Academy of Pediatrics and the US Surgeon General.

Related Links:
Center for Autism and Related Disorders
Lineagen



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.